Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders.

Corradini P et al. Methods Mol Biol. 2014;1109:209-37. doi: 10.1007/978-1-4614-9437-9_12.

Clinical Contribution of PET/CT in Myeloma: From the Perspective of a Radiologist.
Nakamoto Y. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):10-1. doi: 10.1016/j.clml.2013.12.005. Epub 2013 Dec 21.

Prognostic value of 1p deletion for multiple myeloma: a meta-analysis.
Ouyang J et al. Int J Lab Hematol. 2014 Jan 27. doi: 10.1111/ijlh.12189. [Epub ahead of print].

The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.
Brioli A et al. Expert Rev Hematol. 2014 Jan 10. [Epub ahead of print].

Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma.
Shin SJ et al. Korean J Pathol. 2013 Dec;47(6):526-33. doi: 10.4132/KoreanJPathol.2013.47.6.526. Epub 2013 Dec 24.

A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide.
Alzoman NZ et al. J Immunoassay Immunochem. 2014;35(2):130-8. doi: 10.1080/15321819.2013.824898.